The global Assisted Reproductive Technology (ART) Market, valued at US$4.02 billion in 2024, is on a steady growth trajectory, projected to expand at a robust CAGR of 7.0% to reach US$4.29 billion in 2025 and an impressive US$6.02 billion by 2030.
This growth is fueled by the rising prevalence of infertility, largely attributed to stress, changing lifestyles, delayed parenthood, and medical conditions. In parallel, continuous technological advancements—such as preimplantation genetic testing (PGT), embryo freezing, and improvements in in-vitro fertilization (IVF)—have enhanced treatment outcomes and boosted patient confidence in fertility therapies.
However, the market also faces challenges, including ethical and regulatory barriers, high treatment costs, and ongoing debates over embryo handling and surrogacy laws. Despite these challenges, supportive government initiatives, shifting societal perceptions, and increased public awareness are driving broader acceptance and accessibility of ART worldwide. Additionally, rising disposable incomes and better healthcare infrastructure in developing nations are paving the way for accelerated growth in fertility care services.
Download PDF Brochure: MarketsandMarkets Report
Market Segmentation Overview
By Type
Equipment holds the largest share of the global ART market in 2024, reflecting the critical role of advanced instruments in modern fertility treatments. Key equipment such as incubators, micromanipulators, imaging systems, and cryopreservation devices are essential for procedures like IVF, embryo culture, and gamete freezing.
The demand for precision, automation, and reliability in ART laboratories continues to rise as clinics aim to enhance success rates and streamline workflows. Furthermore, the growing number of fertility clinics, increased adoption of assisted reproduction technologies, and ongoing R&D in reproductive medicine are collectively boosting this segment’s growth and maintaining its market dominance.
By Technology
In-vitro Fertilization (IVF) remains the dominant technology within the ART market, owing to its high success rate, widespread application, and constant technological evolution. IVF effectively addresses a wide range of infertility causes, including age-related infertility, male-factor infertility, and unexplained fertility issues.
Recent innovations—such as time-lapse embryo imaging, cryopreservation, and preimplantation genetic screening (PGS)—have significantly increased the efficiency and success of IVF treatments. The rising trend of medical tourism for fertility treatments, government initiatives supporting ART, and the growing establishment of fertility centers globally further reinforce IVF’s market leadership.
With rising infertility rates and greater awareness of reproductive options, IVF continues to be the most sought-after fertility treatment worldwide.
By Care Settings
The fertility clinics segment commands the largest share of the global ART market among care settings. Fertility clinics are at the forefront of reproductive care, providing a comprehensive suite of services—including IVF, intrauterine insemination (IUI), egg and sperm cryopreservation, and preimplantation genetic testing (PGT).
These facilities combine state-of-the-art technology, specialized laboratories, and experienced reproductive specialists to deliver higher success rates and improved patient experiences.
The growing number of private fertility centers, government-backed subsidies, and increasing medical tourism—particularly in India, Thailand, and Spain—are also contributing to the segment’s dominance. As patient awareness and accessibility improve, fertility clinics are expected to remain the primary destination for ART treatments globally.
By Geography
The Asia-Pacific region is projected to experience the fastest growth in the ART market through 2030. The region’s expanding demand for fertility treatments is driven by lifestyle changes, delayed family planning, and rising stress-related infertility.
Countries such as India, China, Japan, and South Korea are witnessing a surge in fertility clinics supported by government initiatives, favorable regulations, and improved healthcare infrastructure.
Furthermore, lower treatment costs, increasing medical tourism, and growing social acceptance of fertility preservation techniques—such as egg freezing and surrogacy—are accelerating market growth. The rising middle-class population with greater disposable income also contributes to long-term market expansion across the region.
📘 Request Sample Pages: Get Report Sample
Leading Companies in the Assisted Reproductive Technology Market
Key players in the ART market are implementing both organic and inorganic growth strategies—including product launches, partnerships, acquisitions, and global expansions—to strengthen their market positions. Prominent players include:
CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), Thermo Fisher Scientific Inc. (US), LENUS Pharma GesmbH (Austria), Zita West (UK), Kitazato Corporation (Japan), Exeltis USA, Inc. (US), Vitabiotics Ltd (UK), FertiPro NV (Belgium), and AdvaCare Pharma (US).
CooperSurgical Inc. (US)
CooperSurgical Inc., a subsidiary of The Cooper Companies, is a leading global provider of medical devices and fertility solutions. The company operates through renowned brands such as ORIGIO (IVF products), Reprogenetics (genetic testing), and Life Global (IVF laboratory solutions).
With operations in over 100 countries, CooperSurgical’s vast distribution network and focus on innovation make it a cornerstone in the global fertility and women’s health industry.
FUJIFILM Irvine Scientific (Japan)
FUJIFILM Irvine Scientific specializes in advanced culture media, embryo transfer solutions, and diagnostic tools that enhance IVF success rates. The company’s strategy emphasizes continuous innovation, global expansion, and strategic collaborations with fertility clinics and research institutions.
By investing in acquisitions and R&D, FUJIFILM Irvine Scientific continues to strengthen its global footprint and deliver reliable solutions to support both clinicians and patients in the field of reproductive medicine.
Vitrolife (Sweden)
Vitrolife is a pioneer in the development and production of high-quality instruments, systems, and culture media used in assisted reproduction. Its diverse product portfolio includes solutions for sperm preparation, oocyte retrieval, IVF, ICSI, embryo culture, transfer, vitrification, and slow freezing.
Vitrolife is recognized for being among the first to provide ready-to-use, high-standard culture media to IVF clinics. The company’s time-lapse technology, cryopreservation systems, and advanced disposable instruments make it one of the most trusted names in global reproductive care.
Future Outlook
The Assisted Reproductive Technology Market is entering an era of transformation—driven by technological breakthroughs, improved accessibility, and shifting societal attitudes toward fertility treatments.
As awareness grows and governments support reproductive health initiatives, ART procedures are becoming increasingly mainstream. Asia-Pacific will remain a key growth engine, while technological innovations and cross-border collaborations will continue to shape the global landscape.
With ongoing research, expanding fertility clinic networks, and growing demand for personalized treatment options, the ART market is poised for sustained and innovative growth through 2030.
For more information, Inquire Now!
